Win-win cooperation | Boteng Co., Ltd. and Baifan Biotech reached a strategic cooperation to jointly build a new ADC drug development and production supply chain ecosystem

On December 20, 2024, Chongqing Boteng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Boteng Co., Ltd.”, “Boteng”) and Baifan Biotechnology (Shanghai) Co., Ltd. (Guilin Sanjinsun Company, hereinafter referred to as “Baifan Biology”) formally signed a strategic cooperation agreement in Guilin. The purpose of this cooperation is to develop in-depth cooperation around R&D, production and supply chain integration of antibody-conjugated drugs (ADCs). Mr. Ju Nianfeng, Chairman and General Manager of Boteng Co., Ltd., Mr. Zou Xun, Chairman of Guilin Sanjin, and Mr. Tan Kai, General Manager of Baifan Biotech attended the signing ceremony.

As an industry-leading end-to-end integrated CDMO company, Boteng Co., Ltd. has a world-leading technology platform and rich experience in delivering successful projects in the fields of conjugated drugs such as small molecules, peptides and oligonucleotides, ADC (containing antibodies, payload-linker, conjugation, formulation cans), and cell and gene therapy drugs. Baifan Biotech has unique advantages in the development of various biopharmaceuticals such as monoclonal antibodies, double antibodies, and fusion proteins. The two sides will integrate R&D resources, technical strength and production capacity in the ADC pharmaceutical field, form a close cooperation mechanism through supply chain resource sharing and complementary advantages, and jointly build a one-stop service cooperation platform for the entire process of ADC (including antibodies, payload-linker, coupling, formulation filling) drugs from stock solution to formulation, from early R&D to commercial production. Based on this cooperation, the aim is to further shorten the ADC drug development cycle, enhance service and delivery capabilities and market competitiveness, and provide global customers with more efficient and reliable one-stop CMC solutions for ADC drugs.

Ju Nian Feng

Boteng Co., Ltd.

Chairman and General Manager

At the ceremony, Ju Nianfeng, chairman and general manager of Boteng Co., Ltd., said that this strategic cooperation is significant. It will not only help enhance the competitiveness of their respective businesses, but will also bring more innovative results to the pharmaceutical industry. In the future, Boteng will continue to use the advantages of its conjugated drug platform, continuously improve platform capabilities, and work with Bai Fan to help global customers accelerate the R&D process, so that good drugs can benefit the public sooner.

Zou Xun

Guilin Sanjin

Chairman

At the ceremony, Zou Xun, chairman of Guilin Sanjin, said that this cooperation not only represents the deep integration of the two companies in business, but also contributes to the development of global ADC drugs by continuously deepening cooperation, leveraging their respective resource advantages and working together.

In the future, Boteng Co., Ltd. and Baifan Biotech will use the overseas Takahashi (Boteng) and Shanghai Lingang (Baifan) as their base operations, continue to adhere to the concept of “making good medicine benefit the public sooner”, and work together to build a new quality ecosystem of sustainable medicine that radiates the world. Through technological innovation and model innovation, we will improve overall efficiency while completing resource integration and improving overall efficiency, and jointly promote the healthy and rapid development of the global ADC pharmaceutical industry.

Established in 2005, Chongqing Boteng Pharmaceutical Technology Co., Ltd. mainly provides one-stop customized R&D and production services for small molecule drugs, peptides and oligonucleotide drugs, protein and conjugate drugs, and cell and gene therapy drugs required for the entire life cycle from pre-clinical research to drug marketing. We are committed to providing customers with excellent global, end-to-end CDMO services, so that good medicine can benefit the public sooner. As of June 30, 2024, the company has established business contacts with more than 1,000 customers around the world and has delivered more than 3,500 successful projects. We have R&D, production and operation at more than 20 sites in China (Chongqing, Shanghai, Sichuan, Jiangsu, Jiangxi, Hubei), the United States, Slovenia, Belgium, Switzerland and Denmark, and employs more than 4,300 people worldwide. On January 29, 2014, the company's stock was listed on the Shenzhen Stock Exchange GEM. Stock abbreviation: Boteng shares, stock code: 300363.

Boteng protein and antibody conjugate drug CDMO service platform

Boteng Protein and Conjugates (Conjugates) CDMO service platform has multiple R&D centers and GMP production bases in Shanghai, China and New Jersey, USA. It can provide global pharmaceutical companies and new drug R&D institutions with end-to-end integrated CDMO solutions for biological and conjugated drugs required from pre-clinical development to commercial marketing. The main services include: Payload-Linker preparation, conjugate drug pharmacogenicity research, cell line construction, upstream and downstream process development, conjugation process development, formulation development, analytical method development, biological and conjugate drug solution (DS) and formulation (DP) GMP production, stability research, production of clinical use of conjugated drugs, and pharmaceutical data support required for application.

Guilin Sanjin Pharmaceutical Co., Ltd. is the core enterprise of the Sanjin Group. It specializes in the development and production of proprietary Chinese medicines and natural medicines, and is one of the earliest domestic manufacturers to produce modern traditional Chinese medicine preparations. Since 1985, Guilin Sanjin has insisted on reform and innovation. Relying on scientific progress and scientific management, it has transformed from a small Chinese medicine workshop into a nationally renowned modern Chinese medicine enterprise, ranking among the top 50 Chinese medicine industry in China. The company has successively won honors such as the National Enterprise Management Outstanding Contribution Award, the National Outstanding Enterprise for Ideological and Political Work, the National Civilized Unit, the National Outstanding Enterprise in the Chinese Medicine Industry, the National Technological Innovation Demonstration Enterprise, the National Intellectual Property Demonstration Enterprise, the National Quality Benchmark, the China Quality Award Nomination Award, and the Chinese Time-honored Brand.

Established in 2016, Baifan Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise focusing on CDMO/CMO services for antibody protein drugs. It is committed to providing peers with one-stop services for antibody drugs from sequence to IND, clinical sample production to BLA and commercial production. Baifan Biotech has built the first domestic non-cross-antibody factory in the Lingang New Area of Shanghai, with a total investment of 0.69 billion yuan, and the maximum production scale of the stock solution can reach 12,000 L. The base complies with the cGMP standards in China, the US and Europe, and has passed the EU QP audit. Its unique NONCROS® cross-antibody production platform can meet the compliance requirements for co-line production of multiple products. The overall operating efficiency is high and the cost advantage is obvious. The company has established cooperative relationships with more than 100 biomedical companies at home and abroad, successfully delivered 50+ antibody protein projects, and promoted 3 BLA projects. It is expected that commercial projects will be put into production by the end of 2025.

Boteng Co., Ltd. provides one-stop service solutions for global pharmaceutical companies, biotechnology companies, scientific research institutions, etc. for small molecule drugs, peptides and oligonucleotide drugs, protein and conjugate drugs, and cell and gene therapy drugs for the entire life cycle from pre-clinical research to drug marketing. The R&D, production and operation sites cover China (Chongqing, Shanghai, Sichuan, Jiangsu, Jiangxi, Hubei), the United States, Slovenia, Belgium, Switzerland and Denmark. We are committed to being customer-centric, providing customers with excellent global, end-to-end CDMO services, so that good medicine can benefit the public sooner.

130K Views